Sign In
Buy GALT
$2.97
-0.260 (-8.05%)
At Close: Jul 31, 2026
Galectin Therapeutics: The Galectin Signature - Signed, Sealed, And About To Be Delivered
06:07pm, Friday, 16'th Apr 2021
Recent immuno-oncology publications further confirm the Galectin Signature in cancer immunotherapy. In a rare and important combination of clinical effects, belapectin, Galectin's galectin-3 inhibitor
GALT Stock: Over 25% Increase Pre-Market Explanation
07:53am, Wednesday, 14'th Apr 2021
The stock price of Galectin Therapeutics Inc. (NASDAQ: GALT) increased by over 25% pre-market. This is why it happened.
Combination therapy with belapectin suggests a better objective response rate with fewer adverse events than pembrolizumab (KEYTRUDA®) alone Combination therapy with belapectin suggests a better obje
Galectin Therapeutics Stock Price Increased 35.27%: Why It Happened
09:06pm, Tuesday, 06'th Apr 2021
The stock price of Galectin Therapeutics Inc. (NASDAQ: GALT) increased by 35.27%. This is why it happened.
Galectin Therapeutics Reports Fiscal 2020 Financial Results and Provides Business Update
08:00am, Wednesday, 31'st Mar 2021
NORCROSS, Ga., March 31, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and p
Galectin Therapeutics, Inc. to Present at the 4th Annual Digital NASH Summit on December 17, 2020
08:00am, Friday, 11'th Dec 2020
NORCROSS, Ga., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Pol F. Boudes, M.D
Galectin Therapeutics Inc. Recaps Results of Annual Meeting of Stockholders Presentation
04:17pm, Friday, 04'th Dec 2020
Chairman Dick Uihlein, CEO and President Joel Lewis, and Chief Medical Officer Pol Boudes Provide Corporate Highlights on Company's Three Active Clinical Trials Chairman Dick Uihlein, CEO and Presiden
Galectin Therapeutics Provides Business Update And Reports Financial Results for the Quarter Ended September 30, 2020
08:00am, Monday, 09'th Nov 2020
Innovative Phase 2b/3 NASH-RX Trial in NASH Cirrhosis Initiated
GM debuts electric Hummer pickup
05:00am, Friday, 23'rd Oct 2020
With the new truck, GM is seeking to retain its traditional strength in pickups
By DAVID WELCH GENERAL Motors Co (GM) showed its much-anticipated battery-powered Hummer pickup in an online video,
By DAVID WELCH GENERAL Motors Co (GM) showed its much-anticipated battery-powered Hummer pickup in an online video,
GM shares close at new year-to-date high following Hummer EV debut
09:24pm, Thursday, 22'nd Oct 2020
GM stock closed at 37.41, up 4.6% – pushing shares for the year in the black (up 2.2%) for the first time since Jan. 2.
Tesla Inc. stock rises Thursday, outperforms market
08:25pm, Thursday, 22'nd Oct 2020
Shares of Tesla Inc. inched 0.75% higher to $425.79 Thursday, on what proved to be an all-around positive trading session for the stock market, with the...
Electric Vehicle Investment Roadmap
03:44pm, Thursday, 22'nd Oct 2020
Electric Vehicles (EVs) are an emerging set of technologies with enormous potential to transform transportation.
GM Pours Billions Into EV Production at Factory ZERO, Spring Hill - The News Wheel
03:39pm, Thursday, 22'nd Oct 2020
GM recently unveiled the new Factory ZERO facility devoted to EV production and announced that Spring Hill will build EVs, too.
GM Models Are the Most American-Made Vehicles - The News Wheel
02:59pm, Thursday, 22'nd Oct 2020
Based on its performance in two studies, GM currently has the most American-made vehicles. Learn more about the studies' findings.
Self-Driving's Latest Turn: GM's Cruise Seeks OK for Cars Without Steering Wheel, Pedals
12:45pm, Thursday, 22'nd Oct 2020
Self-driving car maker Cruise said on Wednesday it and majority shareholder General Motors Co. would seek U.S. regulatory approval in coming months to
